RH disease

(redirected from Rh isoimmunization)
Also found in: Dictionary.
Related to Rh isoimmunization: Coombs test

RH disease

Patient discussion about RH disease

Q. Explain RH please

A. Rh...? as the blood type Rh? or you meant to ask about RA which is Rheumatoid Arthritis.
if you seek information about the blood type, here is something that will help you understand:
http://www.nlm.nih.gov/medlineplus/ency/article/003345.htm

if RA is what you are looking for, here is a great tutorial that will do it nicely:
http://www.nlm.nih.gov/medlineplus/tutorials/rheumatoidarthritis/htm/lesson.htm

More discussions about RH disease
References in periodicals archive ?
The most common adverse reactions in suppression of Rh isoimmunization with Rhophylac are nausea, dizziness, headache, injection-site pain, and malaise.
Procurement Framework Agreement for the Supply Drugs for Hiv-Aids Program and the National Program for Prevention of Rh Isoimmunization Syndrome - 9 Lots Lot 1 Abacavirum 20 Mg Ml; Lot 2 Darunavirum 400 Mg; Lot 3-Emtricitabinum 200 Mg; Lot 4-Lamivudinum 10Mgml; Lot 5-Lopinavir Ritornavir 80 Mg Ml 20 Mg Ml; Lot 6 Nevirapinum 200 Mg; Lot 7-Tenofovirum Dispoproxil Fumarate 245 Mg; Lot 8-D Immunoglobulin 625 Iu Ml Sol Inj Ml; Lot 9 - Darunavirum 600 Mg.
Rh isoimmunization can be suppressed by treating the mother with an Rho (D) Immune Globulin product, such as WinRho SD, which reduces the toxic reaction.
of Winnipeg, Canada to manufacture WinRho SD(TM) (Rho (D) Immune Globulin Intravenous (Human)) for the suppression of Rh isoimmunization, and the treatment of children with chronic and acute immune thrombocytopenic purpura (ITP), adults with chronic ITP, and children and adults with ITP secondary to HIV infection.
NABI also has two immunotherapeutic products already on the market: H-BIG, for the prevention of hepatitis B, and WinRho SD(R), for the treatment of idiopathic thrombocytopenic purpura [ITP, an immune platelet disorder], and for the suppression of Rh isoimmunization.
NABI also has two immunotherapeutic products already on the market: H-BIG(R), for the prevention of hepatitis B, and WinRho SD(R), for the treatment of Immune Thrombocytopenic Purpura [ITP, an immune platelet disorder], and for the suppression of Rh isoimmunization.
NABI also has two immunotherapeutic products already on the market: H-BIG(R), for the prevention of Hepatitis B, and WinRho SD(R), for the treatment of Immune Thrombocytopenic Purpura (ITP), an immune platelet disorder, and for the suppression of Rh isoimmunization.